Many approach CI in oncology through the same lens as other therapeutic areas, but doing so may inadvertently lead to an unawareness of the landscape. As a result, stakeholders making strategic decisions may be at risk of doing so based on inaccurate or outdated intelligence. Today’s workshop will translate key learnings from Molekule’s experience in oncology into best practices for those starting or entering into a new CI program in oncology.
In this workshop, participants will identify appropriate sources for monitoring the oncology landscape, then practice discerning a major event from an immaterial event and translating this into an actionable real-time alert that maximizes impact for all stakeholders. This will be followed by a review of the alert to help build awareness and vigilance regarding best practices in oncology.
This Workshop is facilitated by Dr. Paul De Santis (PharmD), Senior Director of Molekule Consulting, a global competitive intelligence and strategy consultancy dedicated to the life sciences and biopharmaceutical verticals. Paul has 15+ years’ experience in oncology spanning clinical and translational research through commercialization. Paul is a Subject Matter Expert in lymphoma, multiple myeloma, and cell therapy; with a passion for CAR T commercialization and maximizing patient access to CAR T.
We call this ecosystem the DrugOme™. The DrugOme™, supports analyses for the strategic decisions of many groups in a therapeutic area agnostic way across all phases of drug development, from discovery through commercialization. We discuss the challenges involved in translating technology-driven insight into action across many groups in many companies and across all phases of drug development.
Topics we will cover:
• What are the 10 “commandments” to build a successful CI team
• What is needed to make the CI team relevant and impactful for a company
• How to recruit the best CI talent into the department and retain them
The audience can expect to be able to participate actively in the “conversation” and contribute to the program
• Information management from public domain: sifting through the ‘noise’
• Using the hybrid of technology and human touch to create successful outcomes
• Case study: ASCO2021
In one of the most rapidly-changing industries in the world, how do you ensure you’re staying on top of new developments while also surfacing relevant insights quickly to your leadership team?
Join experts, Diana Gowe, Director, Strategy, Analytics & Business Transformation at Johnson & Johnson, and Craig Farrell, Director of GTM Strategy, Life Sciences at AlphaSense, as they share the success secrets behind leading CI teams and why AI is crucial to being first in the market.
In this session, you’ll walk away with:
Game-changing best practices for competitive monitoring so you can deliver quarterly reports faster and more efficiently
Tactics used by Johnson & Johnson’s leading CI team for tracking key competitors (alerts, thematic and KPI extraction, semantic search, and access to broker research)
Real-life examples of how to make the most of your research platform’s customer service team so you never miss a deadline again
Key to this session will be addressing business needs across the lifecycle, whereby participants will:
• Develop an in-depth understanding of how a diverse range of facilitated activities (Rapid Immersion, Threat Assessment and Competitor Simulations) can help deliver strategic and competitive insights within an organization
• Appreciate the importance of leveraging the outcomes of workshops to inform and direct decision making
• Receive hands-on opportunities to apply learnings to a pharma case-study in a learning environment
Using business case studies, real-life experiences and validated theory, the INOVIS team will equip you with a number of go-to techniques that can be rapidly integrated into ongoing CI Practice, whether you’re a seasoned CI professional veteran, or newer to the field.
Due to the rapid spread of COVID-19 and lack of reliable treatment options at the outset of the pandemic, vaccinations became a viable option to fight the pandemic.
In this presentation, we will review the significant hurdles that the pharmaceutical industry overcame to successfully develop and distribute the vaccines specifically in the US and EU, including:
• scientific advancements, including use of mRNA-based technology in vaccines allowed rapid manufacturing
• regulatory streamlining allowing initiation of multiple clinical trial phases and emergency authorizations to shorten the developmental timeline
• institutional collaborations and funding initiatives along with unparalleled transparency
• remaining challenges as the pandemic continues and lessons learned for the first wave of vaccine development
Specifically this presentation will enable you to:
• Advance your understanding of core Gx/biosimilar market dynamics and corresponding CI solutions
• Set up a best-in-industry Gx/biosimilar regulatory intelligence (RI) and CI tracking program
• Understand Gx / biosimilar product development and entry strategies
o Technology is also enabling democratization of data and insights through self-service and collaboration platforms, thus enabling CI teams to provide more impact.
Please join us as we walk you through the steps ahead to integrate additional important data into your clinical trial landscape and bring untapped value to your forecasting, BD and Portfolio partners.
Applying artificial intelligence to more efficiently gather, organize, and synthesize key data allows teams to draw out these key insights even within rapidly changing environments.
This presentation will explore:
● How a healthcare specific, AI-based knowledge graph facilitates better data management and analysis
● How the application of AI can reduce costs and allow your team to focus on tasks requiring human-intelligence and higher-order thinking
● How AI can provide your team with a more integrated, comprehensive view of your market by bringing together all key data sources (clinical trials, conferences, social media, earnings call reports, press releases, etc.)
Launching a new product is exciting and intense, but transitioning a product from launch to growth requires endurance and deliberation. Furthermore, scaling requires leaders who understand the role of competitive intelligence and how to manage the increased organizational and business complexity of growth.
Having supported numerous blockbuster brands, we have identified three frameworks to help brand leaders achieve high growth. The frameworks are:
• Leading high growth
• Competitive Prioritization Assessment
• Competitive readiness
In this talk, we will introduce the three frameworks. Additionally, we will share how the CI professional can have a greater impact on high-growth brands by shifting focus from strategy to execution.
Presentation attendees will receive a copy of the article “Leading High Growth Ventures” from Harvard Business Publishing. We look forward to seeing you there!
These paths present the changes that must occur for an event to happen, which can then drive competitor and market monitoring. The session will explore how to build an indicator pathway, identify key events along the pathway, and determine specific responses to events. Making the most of the scenario planning results and the indicator pathways also includes building a monitoring system to alert when an indicator event is about to happen and a response for when that event happens. The session will cover processes used to identify what indicators should be monitored, how to monitor, the importance of adjustability within the monitoring program, and how to prepare fast response for when the event occurs
• Use of masks required: Please bring your own if preferred, but masks and hand sanitizer will also be provided.
• Greetings should be socially distanced: no handshakes, hugs, or kisses, etc.
• Meeting space will accommodate more spacing between attendees.
• The hotel experience will be entirely revamped with specific cleaning protocols.